Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
about
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsAnalyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesChemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cExhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsAntigenic modulation and rituximab resistance.Rituximab: therapeutic benefit! Vitamin R?Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesThe clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.Subcutaneous Administration of Monoclonal Antibodies in Oncology.Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
P2860
Q26849243-CA51FE92-4DDF-4971-8ADA-E74090AEB1C8Q27694769-0BCE3CFD-BFC4-4A2F-BC68-33FB5EF227D3Q30408922-7BD09171-3A1F-4377-847E-778A17FFBE62Q30421637-D452C506-8916-4600-9296-DA26F0CDAA8EQ30432874-77888A7A-B82C-411C-90A2-323CB82DD610Q33764056-FBB65EF4-2D5C-4995-B23A-5147DD24071EQ33795160-D3D6B4E7-C59A-4270-A8E8-71ADF8BA488CQ34310845-DACD427B-8C88-4686-9A4A-D65E8EBBD8D6Q34622755-F7A421C1-2AF0-4FD1-ACFA-E25884650A87Q34750560-F7406B76-17FE-4252-8297-54EE9BD7CF2CQ36437030-8CA09FC4-61C3-4B2B-937C-98C9748CF9CBQ36725445-C73DA58F-7516-4C0D-86D9-FC9F6ABA2126Q37919869-912C1A33-C814-4B20-8BE8-FD7243632A0DQ39013196-C4A8A8EE-CF07-4F37-8D69-A7D608567D40Q40519355-3779335A-0022-4E51-80BC-4C26213FC973Q41791356-5109C46D-1110-4345-B1BD-80D1427FC114Q42065760-6230EEEA-4D79-4F9E-9301-01AA3B99C0BFQ42428917-785740CB-32A9-4673-98EE-7BBFA0DAFDA2Q45009828-B1F35D5F-C9BC-46D5-A0FC-1E7F694D3840Q48367614-9C01E6C9-20D1-44D9-9EB5-79137DD6B5D1
P2860
Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@ast
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@en
type
label
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@ast
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@en
prefLabel
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@ast
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P1433
P1476
Fractionated subcutaneous ritu ...... chronic lymphocytic leukemia.
@en
P2093
Adrian Wiestner
Andrew W Pawluczkowycz
Berengere Vire
Margaret A Lindorfer
Paul V Beum
Ronald P Taylor
Thomas Hughes
P2860
P304
P356
10.3324/HAEMATOL.2009.012484
P577
2009-08-13T00:00:00Z